Trials / Completed
CompletedNCT05419388
A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma
A Randomized, Open-Label, Multicenter, Phase II Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 93 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics of two dose levels of RO7247669 in participants with unresectable or metastatic melanoma to select the recommended dose for further development.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RO7247669 | Participants will receive intravenous (IV) RO7247669 Q3W |
Timeline
- Start date
- 2022-08-15
- Primary completion
- 2024-05-01
- Completion
- 2025-11-27
- First posted
- 2022-06-15
- Last updated
- 2026-02-04
Locations
22 sites across 10 countries: Australia, Brazil, Canada, Czechia, Greece, New Zealand, Poland, Slovakia, Spain, Turkey (Türkiye)
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05419388. Inclusion in this directory is not an endorsement.